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ABSTRACT 
 
 
Recent studies demonstrated that the expression pattern of bone morphogenetic protein 7 
(BMP-7) is altered in different tumors. We determined expression of BMP-7 in human clear 
cell renal carcinoma (CCRC). 
Samples from cancer and corresponding healthy tissue were obtained from 20 patients who 
underwent nephrectomy for CCRC. Expression of BMP-7 mRNA was determined by RT-
PCR and protein expression was analyzed by immunohistochemistry.  
RT-PCR showed strong downregulation of BMP-7 mRNA in cancer tissue. 
Immunohistochemistry revealed expression of BMP-7 in normal renal tissue, with almost 
complete loss of BMP-7 expression in malignant cells of 6 patients (30%). After 3 years of 
follow-up, 5 out of 6 patients with high BMP-7 mRNA expression were alive and disease-
free, compared to 9 out of 14 patients with low BMP-7 mRNA expression.  
BMP-7 mRNA and protein expression were downregulated in CCRC. Further prospective 
studies are needed to characterize the role of BMP-7 in human CCRC. 
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INTRODUCTION 
 
Bone morphogenetic proteins belong to the transforming growth factor β (TGF-β) 
superfamily (1). Although first identified by their capacity to promote bone formation (2), 
they were found to play important roles in prenatal body patterning and morphogenesis, while 
during the postnatal life they may be involved in pathogenesis of different diseases (3,4). 
Bone morphogenetic protein-7 (BMP-7) is a 35-kDa homodimeric protein, predominantly 
synthesized in the kidney (5). BMP-7 knock-out mice die during the first postnatal day from 
uremia due to renal hypoplasia (6,7). In postnatal life, BMP-7 was found to be important in 
preservation of kidney structure and function and amelioration of injury. It inhibits tubular 
cell dedifferentiation, mesenchyme transformation, apoptosis, and protects kidney from 
diabetic nephropathy, acute and chronic renal failure (8-11). Dysregulation of BMP signaling 
has been suggested in carcinogenesis (12-18). 
The clinicopathological significance of BMP-7 in human clear cell renal carcinoma has not 
been fully elucidated. We investigated BMP-7 mRNA and protein expression in samples of 
renal clear cell carcinoma and determined their prognostic significance after 3 years of 
follow-up.  
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METHODS 
 
Tissue samples 
Tissue samples were obtained at the Department of Urology, University Hospital Zagreb, 
Zagreb, Croatia, from 25 consecutive patients who underwent nephrectomy for renal cancer. 
Investigations were approved by the hospital ethic committee. Besides the abdominal multi-
slice computed tomography, all patients underwent bone scan and chest X-ray to exclude 
disease dissemination before surgery. Tumor samples and corresponding healthy parts taken 
from the normal tissue located as far as possible from the tumor site were frozen in liquid 
nitrogen immediately after surgical resection, and were kept at -90°C until RNA extraction. 
Out of 25 tumor samples, there were 20 clear cell carcinomas that were further processed and 
these patients were included in investigation. Patients were followed-up for at least 3 years 
after surgery. 
 
Quantitative Real-time RT-PCR 
 
Messenger RNA (mRNA) was isolated from normal and cancer renal tissue using Quick 
PrepmRNA purification kit (GE Healthcare, UK) according to the manufacturer's instructions. 
The quantity and quality of mRNA was guaranteed by manufacturer. 
Real-time RT-PCR was performed with a Light Cycler (Roche Applied Science, USA). Three 
micrograms of mRNA was reverse transcribed in reaction volume of 20 µl using FirstStrand 
cDNA synthesis kit (Amersham Biosciences, UK). The product was diluted to a volume of 50 
µl, and 5 µl aliquots were used as templates for amplification using LC FastStart DNA Master 
SYBR Green I (Roche, USA) and gene-specific primers for BMP-7. Specific primers for each 
gene transcript were designed using previously published primers (sequence checked using 
GeneBank) and checked as to whether they showed a single peak in the dissociation curve. 
The primers for BMP-7 (276 bp) were: forward CAG CCT GCA AGA TAG CCA TT, and 
reverse GAG CAG GAA GAG ATC CGA TT (19).  
For the analyses of the different genes, a separate master mix was made up for each primer 
pair and contained a final concentration of 1x LC FastStart Reaction Mix SYBR Green I 
(contains reaction buffer, LC FastStart Enzyme, dNTPs, SYBR Green I dye and 10 mM 
MgCl2), 0,5 µM primers and 3 mM MgCl2. Monitoring was done according to the 
manufacturer’s instructions, as described previously (20). In brief, a master mixture was 
prepared on ice, containing 1 µl cDNA, 2 µl LC DNA Master SYBR Green Mix I mix, 50 ng 
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primers, and 2.4 µl 25 nmol/L MgCl2. The amplification conditions of the 40 cycles consisted 
of denaturation at 95°C for 10 s, annealing at 65°C for 10 s, and extension at 72°C for 10 s. 
Obtained products were subjected to a temperature gradient from 68°C to 95°C at 0.1°C/s 
with continuous fluorescence monitoring to produce melting curves. All experiments were 
performed in triplicates. Quantification of housekeeping gene was performed with LC h-
PBGD Housekeeping Gene Set according to the manufacturer's instructions (Roche, 
Germany).  
 
Immunohistochemistry 
Paraffin sections (3-4 µm) were deparaffinised in xylene and then rehydrated through 
graded alcohol. Endogenous peroxidase activity was blocked with 0,3 % hydrogen 
peroxide for 10 min. Anti – human BMP-7 monoclonal antibodies (R&D Systems, 
USA) were used for immunohistochemistry. Immunostaining was performed by the 
avidin biotin peroxidase complex method using LSAB+ kit (Dako, Glostrup, 
Denmark).  
 
Evaluation of immunohistochemistry 
Results of immunohistochemistry were interpreted using a light microscope. BMP-7 
immunostaining was semiquantitatively evaluated for intensity (0, negative; 1 weak; 2, 
moderate; 3, strong staining). 
 
Statistical analysis 
SAS for Windows, version 9.1 (SAS Institute, Cary, USA) was used to perform statistical 
calculations. P<0.05 was considered statistically significant.  
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RESULTS 
 
Patients’s characteristics 
There were 12 male and 8 female patients age ranging from 39 to 83 years (mean 63 years). 
The classic urological triad of haematuria, flank pain, and palpable mass was present in only 
one patient (5 %). Clinical findings at presentation are listed in Table 1.  
 
Table 1. 
 
Twelve patients had stage I, and 8 patients stage II of renal clear cell carcinoma according to 
Robson (21). Malignancy was an incidental finding on routine examination in 6 patients. 
Sixteen patients had one or more concomitant diseases including urolithiasis, diabetes 
mellitus, valvular heart disease and angina pectoris. One patient had previously been treated 
for malignant disease (acute myeloid leukaemia).  
 
RT-PCR analysis of BMP-7mRNA expression in normal renal tissue versus renal clear cell 
carcinoma 
 
Samples were initially obtained from 25 patients, but histological examinations demonstrated 
diagnosis of clear cell carcinoma in 20 patients, while oncocytomas and chromophobe tumors 
were excluded from investigation. Thus, forty kidney specimens obtained from 20 patients 
were evaluated for BMP-7 mRNA expression. 
Under the conditions employed, BMP-7 mRNA expression was noted in all non-tumor renal 
tissue specimens and all renal clear cell cancer samples. The relative level of BMP-7 mRNA 
expression was determined with the reference to the internal PBDG control. Graph 1. shows 
ratio of BMP-7 mRNA expression normalized for PBGD expression in healthy and malignant 
tissue. Absolute numbers were transformed to logarithm scale because of huge differences in 
expression between the samples. It is evident that 17/20 patients had strongly downregulated 
BMP-7 mRNA in malignant tissue compared to healthy kidney parenchyma (up to 6.841 
times lower BMP-7 mRNA expression normalized for PBGD). One patient exhibited only 
slightly higher level of BMP-7 mRNA expression in cancer compared to healthy tissue, while 
two patients had clear predominance of BMP-7 mRNA expression in malignant part of kidney 
(Graph 1). High ratio between healthy and malignant tissue was consequence of extreme 
downregulation of BMP-7 mRNA expression in malignant tissue.  
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Graph 1. 
 
BMP-7 protein expression by immunohistochemistry 
 
To confirm the above gene expression results demonstrating downregulated BMP-7 mRNA 
expression in malignant renal tissue, immunohistochemical analysis of the BMP-7 protein 
was performed.  
Immunostaining for BMP-7 was stronger (count 1-2) in healthy tissue than in corresponding 
malignant tissue (count 0-1 as explained in Materials and Methods) in 6/20 patients (30 %). 
Interestingly, these were the only samples that exhibit positive staining for BMP-7 protein 
compared to BMP-7 mRNA expression in all samples. In healthy kidney tissue BMP-7 
expression was dominantly localized to tubular cells (Figures 1 A and B).  
 
Figures 1 A and B. 
 
The level of expression of BMP-7 mRNA correlated with level of protein expression. 
Samples obtained from patients with high BMP-7 mRNA expression on RT-PCR examination 
demonstrated positive BMP-7 staining, while samples with low BMP-7 mRNA expression 
stayed negative after BMP-7 immunohistochemistry (count 0). Bone morphogenetic protein-7 
expression was positive in both healthy and less intensively in malignant tissue of all patients 
with highly negative BMP-7 mRNA malignant-to-healthy tissue ratio. Samples from patients 
with positive BMP-7 mRNA malignant-to-healthy tissue ratio did not exhibit BMP-7 protein 
staining neither in healthy nor in malignant tissue. 
 
Low BMP-7 mRNA expression may correlate with poor prognosis 
 
After 3 years of follow-up, 5/6 (83.3 %) patients who exhibit BMP-7 staining on 
immunohistochemistry were alive and disease-free, compared to 9/14 (64.3 %) patients in 
whom immunohistochemical staining failed to demonstrate BMP-7 protein expression 
(p=0.11).  
Bone morphogenetic protein-7 mRNA expression at nephrectomy was more accurate in 
predicting prognosis at 3 years of follow-up. Out of six patients with >-2 fold change in 
expression of BMP-7 mRNA from control (“high” expression group) 5 patients were disease-
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free, and one patient died from heart attack. During the same period 9 out of 14 patients with 
lower BMP-7 mRNA expression remained alive and disease-free. Two patients from this 
group died from disseminated malignant disease, one of them had concomitant acute myeloid 
leukemia. 
 
Comparison of survivors and deceased patients 
 
Out of 6 patients with strongly positive BMP-7 staining in healthy tissue, 5 patients survived, 
and one died (Table 1.). Among the survivors, 16 patients had downregulated and only one 
increased BMP-7 mRNA expression (ratio between expression of BMP-7 mRNA in 
malignant and healthy tissue normalized for expression of PBGD), p<0.05. One deceased 
patient had increased and one downregulated BMP-7 mRNA expression (patient with 
leukemia), while the third exhibited only slightly higher level of BMP-7 mRNA expression in 
cancer compared to healthy tissue.  
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Discussion 
 
To the best of our knowledge, this is the first paper dealing with BMP-7 mRNA expression in 
renal clear cell carcinoma. We found high BMP-7 mRNA expression in the healthy tissue 
relative to the renal clear cell carcinoma. Difference was less intensive although consistent at 
the level of protein expression. This is probably the reflection of different methodology which 
involved signal amplification in RT-PCR. Highly negative ratio between expression of BMP-
7 mRNA in malignant and healthy tissue normalized for expression of PBGD was associated 
with favorable outcome at 3-year-follow-up. It resulted from high level of BMP-7 expression 
in healthy tissue and very low expression in malignant tissue. Kwak et al. have recently 
demonstrated BMP-7 expression in 34.1 % of renal cell carcinomas examined by 
immunohistochemical analysis of 185 cases, with expression rates being higher in 
chromofobe or papillary type than in clear cell type. They showed that patients with bone 
morphogenetic protein-7 expression have better disease-free survival than those without 
expression (22). Our study provided the same results of immunohistochemical analysis (30 % 
positive samples), but demonstrated that BMP-7 mRNA was expressed in both healthy and 
malignant tissue samples, with strong relationship between highly negative BMP-7 mRNA 
malignant-to-healthy tissue ratio and survival.  
Action of BMP-7 is closely regulated not only by precise control of mRNA expression and 
protein processing, but is directed by influences of numerous agonists and antagonists. The 
importance of BMP-7 antagonist SOSTDC1 (sclerostin domain containing-1) in renal cancer 
has recently been investigated by Blish et al. They demonstrated decreased expression of 
SOSTDC1 in renal clear cell carcinoma. SOSTDC1 suppresses BMP-7 induced 
phosphorylation of Smad and Wnt signaling, and restoration of SOSTDC1 in renal clear cell 
carcinoma cell cultures suppresses proliferation (23).  Noggin, a BMP antagonist suppresses 
growth of prostate cancer cells (24). On the other side, gremlin 1, another BMP-7 antagonist 
may enhance proliferation of various malignant cells (25). The story is further complicated 
with the finding of involvement of second messengers in development of neoplasia (26). 
Thus, Smad4, the main intracellular target of BMP signaling, was identified as tumor 
suppressor in pancreatic and intestinal cancer (27), and is required for transforming growth 
factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer 
cells (28). Numerous studies have linked members of BMP family, BMP antagonists, and 
BMP receptors to cancer (12-18). However, available data on involvement of BMP family 
members in cancerogenesis is conflicting. BMP-7 inhibits growth of prostate cancer cells, and 
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was strongly downregulated in malignant tissue compared to correspondent healthy prostatic 
tissue (29). Increased BMP-7 expression was found in various human cancers, including 
malignant melanoma, breast cancer, prostate cancer, ovarian cancer, osteosarcoma and 
colorectal cancer (12-18, 30, 31). To the contrast with previous results, BMP-7 mRNA 
expression was in our study significantly downregulated in cancerous tissue. Considering the 
differences in BMP-7 expression between various organs and its expression during embryonic 
development which is predominantly localized to kidneys, our results supports the hypothesis 
of protective role of BMP-7 in maintenance of adult kidney structure and function (8-11). 
Among the survivors, 16 patients had downregulated and only one increased BMP-7 mRNA 
expression (ratio between expression of BMP-7 mRNA in malignant and healthy tissue 
normalized for expression of PBGD), p<0.05. BMP-7 mRNA was downregulated in a patient 
who died from leukemia, but increased in two other deceased patients. Despite the small 
sample size, we may conclude that survivors had increased BMP-7 mRNA in the healthy 
tissue. 
It is clear that activities and interactions between family members, their receptors and second 
messengers, as well as between agonists and antagonists are complex and may vary. Further 
investigations are needed to determine their exact role and utility as potential therapeutic 
targets in treatment of neoplasia.  
 In summary, our data demonstrate high level of expression of BMP-7 mRNA in normal renal 
parenchyma, with localization to the renal tubular cells. Furthermore, significant 
downregulation of BMP-7 mRNA expression was found in renal clear cell carcinoma. BMP-7 
protein was also downregulated in renal clear cell cancer compared to adjacent healthy kidney 
parenchyma, but with significantly lower difference than at the gene level. BMP-7 may have 
protective role in maintaining structure and function of adult kidneys and its loss may lead to 
development of neoplasia. It is an intriguing possibility that persons with low level of BMP-7 
mRNA expression may be vulnerable for development of renal neoplasia. Further prospective 
studies are needed to better characterize the role of BMP-7 in human clear cell carcinoma and 
to evaluate BMP-7 as a possible new prognostic factor in renal clear cell carcinoma. 
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Graph 1. BMP-7 mRNA expression in tumor tissue relative to healthy tissue (logarithm 
scale). BMP-7 mRNA is normalized for PBGD expression. Patients with ≥-2 fold change in 
expression of BMP-7 mRNA from control belong to the «high» expression group. 
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Table 1. Demographics and clinopathological characteristics of patients with renal clear cell 
carcinoma included in the RT-PCR and immunohistochemical analysis of BMP-7 expression. 
Highly negative ratio between expression of BMP-7 mRNA in malignant and healthy tissue 
normalized for expression of PBGD * (p<0.05). Positive ratio between expression of BMP-7 
mRNA in malignant and healthy tissue normalized for expression of PBGD #. 
 
Variable Survivors (n=17) Deceased (n=3) 
Age (mean, range) 46 (39-65) 67 (56-83) 
Gender (female) 7 1 
Size of tumor (cm), 
mean (range) 
2.5 (2-3.4)  3.8 (2.7-4.8) 
Stage I  12 0 
Stage II 5 3 
Haematuria 3 3 
Flank pain 4 2 
Palpable mass 0 1 
Hypertension 10 0 
Elevated sedimentation 
rate 
10 2 
Thrombocytopenia 0 1 
Anaemia 0 1 
Erythrocytosis 1 0 
Elevated liver 
chemistries 
1 1 
Smoking 6 0 
BMP-7 mRNA 
downregulated * 
16 1 
BMP-7 mRNA 
upregulated # 
1 1 
Positive healthy tissue 
staining for BMP-7 
5 1 
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Figure 1. Immunostaining of BMP-7 was weak in normal renal tissue, but almost completely 
absent in the corresponding renal clear cell carcinoma tissue. Positive staining was mainly 
detected in the cytoplasm of tubular cells. Glomeruli were BMP-7 negative. (A) Healthy renal 
tissue, original magnification x 200, BMP-7 stain; (B) corresponding malignant renal clear 
cell carcinoma tissue, original magnification x 200, BMP-7 stain. 
 
 
 
 
 
